In this study we compared the ability of phenytpin, a microsomal enzyme inducer, to raise plasma high-density lipoprotein (HDL) levels in normolipidemic subjects and patients with primary hypoalphalipoproteinemia. In healthy control subjects, phenytoin caused a dose-dependent increase of plasma HDL, HDL2, and HDL3 cholesterol levels, up to 40% to 50%. Minor changes were recorded in the plasma concentrations of apolipoprotein (ape) A-I and apo A-II; the plasma level of the cholesteryl ester transfer protein (CETP) decreased by 42%. In contrast, none of the patients with hypoalphalipoproteinemia had changes in plasma HDL, HDL2, or HDL3 cholesterol, apo A-I, apo A-II, or CETP levels. These findings indicate that microsomal enzyme inducers are unsuitable to increase plasma HDL levels in highrisk patients with primary hypoalphalipoproteinemia, and they disclose a new mechanism, that is, decreased CETP-mediated transfer of cholesterol out of HDL, for the HDL-raising effect of microsomal enzyme inducers in healthy individuals.
MICROSOMAL-ENZYME INDUCERS RAISE PLASMA HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS IN HEALTHY CONTROL SUBJECTS BUT NOT IN PATIENTS WITH PRIMARY HYPOALPHALIPOPROTEINEMIA / G. FRANCESCHINI, J. WERBA, A. DACQUARICA, G. GIANFRANCESCHI, S. MICHELAGNOLI, C. SIRTORI. - In: CLINICAL PHARMACOLOGY & THERAPEUTICS. - ISSN 0009-9236. - 57:4(1995), pp. 434-440.
MICROSOMAL-ENZYME INDUCERS RAISE PLASMA HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS IN HEALTHY CONTROL SUBJECTS BUT NOT IN PATIENTS WITH PRIMARY HYPOALPHALIPOPROTEINEMIA
G. FRANCESCHINIPrimo
;C. SIRTORIUltimo
1995
Abstract
In this study we compared the ability of phenytpin, a microsomal enzyme inducer, to raise plasma high-density lipoprotein (HDL) levels in normolipidemic subjects and patients with primary hypoalphalipoproteinemia. In healthy control subjects, phenytoin caused a dose-dependent increase of plasma HDL, HDL2, and HDL3 cholesterol levels, up to 40% to 50%. Minor changes were recorded in the plasma concentrations of apolipoprotein (ape) A-I and apo A-II; the plasma level of the cholesteryl ester transfer protein (CETP) decreased by 42%. In contrast, none of the patients with hypoalphalipoproteinemia had changes in plasma HDL, HDL2, or HDL3 cholesterol, apo A-I, apo A-II, or CETP levels. These findings indicate that microsomal enzyme inducers are unsuitable to increase plasma HDL levels in highrisk patients with primary hypoalphalipoproteinemia, and they disclose a new mechanism, that is, decreased CETP-mediated transfer of cholesterol out of HDL, for the HDL-raising effect of microsomal enzyme inducers in healthy individuals.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.